Medivir to present at the Erik Penser Bank Healthcare Day

Rhea-AI Summary

On February 23, 2023, Medivir AB, a pharmaceutical firm focused on cancer treatments, announced its participation in the Erik Penser Bank Healthcare Day. CEO Jens Lindberg will discuss the ongoing clinical study of fostroxacitabine bralpamide (fostrox). The presentation will be accessible on Medivir's website post-event. Medivir aims to address high unmet medical needs in cancer treatment, particularly with fostrox, which targets liver cancer cells while minimizing side effects. Additionally, Medivir collaborates with IGM Biosciences (IGMS) for the development of Birinapant in solid tumor treatments. For more details, visit www.medivir.com.

News Market Reaction – IGMS

-0.78%

-0.78% Session move

In the trading session that priced this news, IGMS declined 0.78%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Medivir AB (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Healthcare Day today, February 23, 2023. CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox).

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3722223/1870311.pdf

Press release (PDF)

 

 

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-erik-penser-bank-healthcare-day-301754125.html

SOURCE Medivir

FAQ

What was discussed in Medivir's presentation at the Erik Penser Bank Healthcare Day on February 23, 2023?

Medivir's CEO Jens Lindberg presented the company's plan for the ongoing clinical study of fostroxacitabine bralpamide (fostrox).

How is Medivir addressing unmet medical needs in cancer treatment?

Medivir focuses on developing innovative drugs like fostrox, targeting liver cancer cells while minimizing side effects.

Who is collaborating with Medivir for the development of Birinapant?

Medivir has an exclusive partnership with IGM Biosciences (IGMS) for Birinapant, aimed at treating solid tumors.

Where can I find the presentation from Medivir's event on February 23, 2023?

The presentation will be available on Medivir's website after the meeting.

What is fostroxacitabine bralpamide (fostrox) used for?

Fostrox is designed to selectively treat liver cancer cells and reduce side effects compared to traditional therapies.